推广 热搜: 生物  cytek  solu  PCR  lumi  Anton  科技  rand  ill  Ademtech 

neuromab

  • 品牌名称:neuromab
  • 发布人:小白鼠网品牌管理员
  • 官网主页http://neuromab.ucdavis.edu/
  • 浏览次数35
  • 更新日期:2019-03-22

neuromab品牌介绍


The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.


The UC Davis/NIH NeuroMab Facility was funded from 2005-2015 with a U24 cooperative grant from NINDS and NIMH, and is currently funded by a High Impact Neuroscience Research Resource Grant (R24). The overall goal of the facility is to generate a library of novel, highly-validated NeuroMabs against neuronal proteins.


The UC Davis/NIH NeuroMab Facility is also accepting suggestions as to potential targets. Requestors should supply the UC Davis/NIH NeuroMab Facility with a scientific justification as to the biological importance of the target molecule, the importance of these reagents to the national neuroscience community, and the availability and suitability of existing polyclonal and/or monoclonal antibodies. Also include a list of reagents (synthetic peptides, fusions proteins, full-length cDNAs for transfection in mammalian cells, samples from knockout mice) that will be made available to the UC Davis/NIH NeuroMab Facility staff to facilitate the development and characterization of these NeuroMabs. Submit this information to NeuroMab here. The UC Davis/NIH NeuroMab Facility advisory board, acting in concert with NIH program officials, will then prioritize the request in the UC Davis/NIH NeuroMab Facility queue. Targets that do not enter the queue are eligible to become fee-for-service projects. Note that all hybridomas and mAbs developed by the UC Davis/NIH NeuroMab Facility are the property of the Regents of the University of California.


The UC Davis/NIH NeuroMab Facility serves as a resource to the entire neuroscience community by providing high quality reagents that will serve as critical links between information emerging from genomic efforts and future proteomic approaches to brain function. Moreover, the unique neuroscience-based approach that the UC Davis/NIH NeuroMab Facility uses will yield reliable antibodies that might not otherwise be available, and the comprehensive biochemical and immunohistochemical verification will save countless investigators the time, money and effort of attempting to use expensive yet suboptimal reagents in their research.


  • A national resource funded by NIH/NINDS to generate and validate novel monoclonal antibodies (NeuroMabs) for neuroscience and other fields of basic biomedical research
  • NeuroMabs are validated for biochemical and immunohistochemical applications in mammalian brain samples, including immunoblotting, immunohistochemistry and array tomography. For perspectives on application-specific antibody validation see Taussig et al., New Biotech 45:1, 2018. PubMed.
  • For information on NeuroMab validation see Gong et al., New Biotech 33:551, 2016. PubMed. See detailed sample preparation and labeling protocols used for NeuroMab validation
  • Plasmids encoding recombinant NeuroMabs are now available from Addgene.  For background information on NeuroMabs that have been cloned and expressed in recombinant form, see Andrews et al., eLife 8:e43322. PubMed.
  • See publications list for peer-reviewed papers showing data obtained with NeuroMabs, now over 2900 publications!
  • Subscribe to our mailing list to receive notifications when new NeuroMabs are added to our collection

产品列表:

Array Tomography

Model Organisms

Disease Targets



neuromab联系方式/代理商


Antibodies Incorporated Contact Info


Antibodies Incorporated

PO Box 1560

Davis, CA 95617-1560

phone: (800) 824-8540 or (530) 758-4400

fax: (530) 758-6307

email: info@antibodiesinc.com

website: www.antibodiesinc.com


0相关评论
联系方式
该会员其他品牌展
网站首页  |  关于我们  |  联系方式  |  网站地图  |  排名推广  |  广告服务  |  积分换礼  |  网站留言  |  RSS订阅  |  违规举报